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Abstract Metformin is the first-line drug treatment for type
2 diabetes. Globally, over 100 million patients are prescribed
this drug annually. Metformin was discovered before the era
of target-based drug discovery and its molecular mechanism
of action remains an area of vigorous diabetes research. An
improvement in our understanding of metformin’s molecular
targets is likely to enable target-based identification of
second-generation drugs with similar properties, a develop-
ment that has been impossible up to now. The notion that 5'
AMP-activated protein kinase (AMPK) mediates the anti-
hyperglycaemic action of metformin has recently been
challenged by genetic loss-of-function studies, thrusting the
AMPK-independent effects of the drug into the spotlight for
the first time in more than a decade. Key AMPK-independent
effects of the drug include the mitochondrial actions that have
been known for many years and which are still thought to be
the primary site of action of metformin. Coupled with recent
evidence of AMPK-independent effects on the counter-
regulatory hormone glucagon, new paradigms of AMPK-
independent drug action are beginning to take shape. In this
review we summarise the recent research developments on
the molecular action of metformin.
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Abbreviations
AMPK 5' AMP-activated protein kinase
CRTC2 cAMP response element-binding protein-
regulated transcription coactivator 2
MATE Multidrug and toxic compound extrusion
OCT Organic cation transporter
PKA Protein kinase A
Introduction
According to national and international guidelines, metformin
is the recommended first-line oral therapy for the treatment of
type 2 diabetes [1–3]. This is down to several factors,
including the impressive safety record of the drug, having been
in clinical use for over 50 years and the fact that metformin
treatment is weight neutral. In addition, there are likely to be
other beneficial effects, including a reduction in cardiovascular
disease and mortality compared with non-intensive treatment
[4] and a possible reduction in cancer incidence, which has
been seen in some [5–7], but not all [8], studies. As metformin
was discovered in the era before modern target-based drug
discovery, the molecular details of its mechanism of action
were not established before it was used clinically and these
continue to be an area of vigorous research. In this review we
discuss what is known and unknown about the molecular
action of metformin.
Molecular action and target of metformin: lessons
and insights from early studies
Chemically, biguanides such asmetformin are composed of two
guanidine groups joined together with the loss of ammonia.
Anti-hyperglycaemic effects have been observed in response
to many, but not all, guanidine-containing compounds. For
metformin, these effects are uniquely dissociated from toxicity.
G. Rena (*) : E. R. Pearson
Cardiovascular and Diabetes Medicine, Ninewells Hospital
and Medical School, University of Dundee, Dundee DD1 9SY, UK
e-mail: g.rena@dundee.ac.uk
K. Sakamoto (*)
Nestlé Institute of Health Sciences SA, Campus EPFL,
Quartier de l’innovation, bâtiment G, 1015 Lausanne, Switzerland
e-mail: Kei.Sakamoto@rd.nestle.com
Diabetologia (2013) 56:1898–1906
DOI 10.1007/s00125-013-2991-0
Before the biguanides, attention was first focused on guanidine
itself [9], which was too toxic for clinical use, then diguanides
(also known as synthalins or diguanidines) [10], composed of
two guanidines connected by an alkyl chain of variable length.
Two diguanides, synthalin A and synthalin B, were used
clinically, but marked toxicity, which could not be dissociated
from therapeutic effects, was noted quite quickly [11, 12]. By
the late 1950s, attention shifted to metformin and two other
biguanides, phenformin and buformin. Even amongst these
biguanides, metformin exhibits a superior safety profile. This is
primarily because the risk of lactic acidosis, which can be fatal,
is much higher for phenformin or buformin treatment [13].
The large quantities of the drug required (up to 2.5 g per day)
for therapeutic effects led early investigators to hypothesise that
it might not depend on a conventional single/specific protein
target. Early physiological studies on the diguanides found that
reduced oxygen consumption accompanied hypoglycaemia
[14]. Later work found that guanidine [15, 16], diguanides [16]
and phenformin [17, 18] reduce mitochondrial oxygen
consumption, suggesting that this organelle is an important site
of action of guanidine-based agents. Several models have been
proposed to account for these effects. The first model was based
on observations that a commonproperty of biguanides and other
guanidines is to change the charge distribution and/or net charge
of membranes [19]. This work showed that these drugs could
inhibit the transport of protons and other cations across
membranes [19]. However, the magnitude of these effects did
not correlate well with anti-hyperglycaemic efficacy, with some
ineffective drugs interacting with membranes much more
readily than either phenformin or metformin [20]. Furthermore,
whilst phenformin has appreciable hydrophobicity and interacts
with membranes, metformin is unusually hydrophilic for a drug
and is unlikely to interact withmembranes significantly. For this
reason, metformin is understood to require transporters to cross
membranes. Another suggestion during this period was that
guanidine-containing drugs induce anti-hyperglycaemic effects
by displacing calcium from proteins such as pyruvate kinase
[21]; however, as in the experiments on membranes, these
effects occurred only at very high concentrations and
hydrophobicity was an important determinant of potency.
Thus, the IC50 by phenformin was 2.5 mmol/l, but the
corresponding value formetforminwas 275mmol/l—far higher
even than the non-specific cation tetramethylammonium [22].
This suggests that the calcium-mobilising effects described are
unlikely to contribute to the therapeutic action of metformin
either. Whether or not calcium-mobilising or lipid effects
contribute to the toxicity of guanidines such as phenformin has
not been thoroughly investigated. It has recently been suggested
that the effects of metformin on the mitochondria depend on
a third non-protein effect—direct targeting of metal ions
[23]—which takes the form of an unusual electron delocalised
planar ring structure, where square planar geometry replaces
more conventional tetragonal geometry [24]. The compelling
evidence of direct binding of metformin to metal ions,
including extensive crystallographic [25] and spectroscopic
analysis [24, 26–28], contrasts with the paucity of evidence
regarding direct binding of the drug to recognised metformin-
regulated proteins. Further work is required to establish how
the metal-binding properties of metformin enable it to mediate
mitochondrial inhibition.
A second important physiological response to biguanides is
reduced gluconeogenesis [29]. Over time, studies on guanidine
derivatives began to link inhibition ofmitochondrial respiration
with reduced gluconeogenesis [30]; however, as already
indicated, the poor correlation of the magnitudes of these
effects for some drugs led others to conclude thatmitochondrial
effects were more likely to contribute towards side effects such
as lactic acidosis rather than therapeutic effects [19, 21]. In the
case of metformin, for example, there is often little impact on
cellular ATP levels, even when using concentrations well
above those likely to be achieved in vivo. These difficulties led
to the suggestion that anti-hyperglycaemic effects might owe
more to drug-specific mitochondrial effects superimposed upon
the general mitochondrial responses to guanide-containing
drugs already described [19]. One such effect of metformin was
found in 2000, in a study of its effects on electron transport, the
mitochondrial oxygen-dependent process that couples the citric
acid cycle to ATP production, providing the bulk of most cells’
energy requirements (Fig. 1). Studies employing hepatocytes,
mitochondria and freeze-clamped livers found that metformin’s
suppression of hepatic glucose output is accompanied by
inhibition of complex I in the mitochondrial electron transport
chain [31, 32]. One key piece of evidence implicating complex I
as the site of metformin action was that the drug inhibited
mitochondrial oxidation of glutamate and malate more
effectively than succinate [31, 32], which as a complex II
substrate, can bypass complex I inhibition. Similar observations
had beenmade earlier using other guanide-containing drugs [15,
16]; however, our understanding of mitochondrial respiration
was probably insufficiently developed to allow this interpreta-
tion of the results at the time. Taken together, these studies
provide compelling evidence of a correlation between inhibition
of electron transport and glucose output. It should be noted,
however, that it has not yet been possible to confirm in genetic
experiments whether or not complex I is the only mitochondrial
target of metformin. For example, it may be significant that
recent studies have found that effects of metformin on
mitochondrial respiration vary between cells, but more work
is required to understand the underlying reason(s) for these
variations [33].
Studies on mitochondrial responses to metformin have
reported that the magnitude of inhibition of gluconeogenesis
is correlated to the extent of inhibition of the respiratory chain
[31]. This suggests that metformin-dependent cellular energy
depletion results in insufficient flux of ATP required to drive
energy-consuming hepatic gluconeogenesis (Fig. 1) [31].
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ATP-/ADP-/AMP-independent effects on pyruvate carbox-
ylase and other enzymes may also contribute to the inhibition
of gluconeogenesis accompanying mild mitochondrial
inhibition [31, 34]. Mitochondrial inhibition also provides
a plausible explanation of lactic acidosis in metformin use, as
lactate accumulation from glycolysis would be predicted to
follow respiratory chain inhibition. Compared with
phenformin and buformin, lactic acidosis is very much less
common with metformin therapy [35–37]. This might be
because metformin-dependent mitochondrial inhibition is
understood to be self-limiting as it depends on the
mitochondria being active [31]. This property might also
explain why metformin is very much less toxic than other
complex I inhibitors, including the neurotoxic pesticide
rotenone [31]. Interestingly, thiazolidinediones, another class
of drugs used for the treatment of type 2 diabetes, are also
mild inhibitors of complex I, and this might contribute to
their anti-hyperglycaemic effect [38].
LKB1–AMPK-dependent pathway as a key molecular
effector of metformin
A key study by Zhou et al in 2001 reported a ‘modern’ signal
transduction effect of metformin on 5' AMP-activated protein
kinase (AMPK) [39] (Fig. 1). AMPK is a critical cellular
energy sensor and regulator of energy homeostasis [40].
AMPK is activated by energy stresses that increase cellular
ADP:ATP and/or AMP:ATP ratios, either by decreasing the
catabolic production of ATP (e.g. via nutrient deprivation and
exposure to mitochondrial toxins) or by promoting ATP
consumption (e.g. by muscle contraction). Zhou et al [39]
hypothesised that AMPK might be an important molecular
effector, as (1) metformin causes a reduction in cellular
ATP:ADP ratios in hepatocytes [31, 32]; and (2) downstream
effects of AMPK activation (e.g. promotion of glucose uptake
and fatty acid oxidation in muscle, inhibition of lipid synthesis
in the liver [41]) simulate the therapeutic effects of metformin.
They demonstrated that metformin indeed stimulates AMPK,
and this stimulation is associated with inhibition of glucose
production in rat primary hepatocytes. They also showed that
metformin treatment decreases levels of sterol regulatory
element-binding protein-1 (SREBP-1), a key lipogenic
transcription factor, at both the mRNA and protein level in
hepatocytes and liver tissue [39]. In addition, they reported that
metformin increases fatty acid oxidation in hepatocytes,
although oral ingestion of metformin resulted in suppression
of whole body lipid oxidation as well as inhibition of hepatic
glucose production in humans [42]. To demonstrate that the
observed effects of metformin are sensitive to changes in the
AMPK-dependent pathway, Zhou et al used a novel small
molecule AMPK inhibitor named compound C. When rat
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Fig. 1 (a, b) Schematic diagram of the anti-hyperglycaemic action of
metformin on the liver cell. Part (b) shows a simplified version of (a).
Metformin is transported into hepatocytes mainly via OCT1, resulting in
an inhibition of the mitochondrial respiratory chain (complex I) through
a currently unknown mechanism(s). The resulting deficit in energy
production is balanced by reducing the consumption of energy in the
cell, particularly reduced gluconeogenesis in the liver. This is mediated
in two main ways. First, a decrease in ATP and a concomitant increase in
AMP concentration occur, which is thought to contribute to the inhibition
of gluconeogenesis directly (because of the energy/ATP deficit). Second,
increased AMP levels function as a key signalling mediator that has been
proposed to (1) allosterically inhibit cAMP–PKA signalling through
suppression of adenylate cyclase, (2) allosterically inhibit FBPase, a key
gluconeogenic enzyme, and (3) activates AMPK. This leads to inhibition
of gluconeogenesis (1 and 2) and lipid/cholesterol synthesis (3), which
may contribute to the longer term metabolic and therapeutic responses to
the drug. FBPase; fructose-1,6-bisphosphatase
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primary hepatocytes were incubated with compound C,
metformin-induced inhibition of acetyl-CoA carboxylase
(a well known target of AMPK involved in lipid metabolism)
and inhibition of glucagon-induced glucose production were
significantly attenuated [39]. However, it should be noted that
several recent publications have shown that, in addition to
AMPK, compound C potently and non-selectively inhibits
numerous other protein kinases and therefore the results
obtained using compound C are not conclusive [43, 44]. It has
been shown that metformin does not directly target AMPK or
affect its phosphorylation by upstream kinases (and phospha-
tases) in cell-free systems. A recent study has provided
compelling evidence that it activates AMPK in an indirect
manner via an increase in AMP:ATP and ADP:ATP ratios
using an engineered cell line expressing AMPK complexes
bearing either the wild-type γ2 isoform or Arg531 → Gly
mutation that renders γ2 complexes insensitive to the effects
of ADP and AMP on phosphorylation [33].
The proposed key role for AMPK in mediating metformin
action was further followed up by Shaw et al in 2005. They
sought to determine the role of tumour suppressor protein
LKB1, an upstream kinase of AMPK, in the liver and
generated a liver-specific Lkb1 (also known as Stk11)
knockout mouse model [45]. They found that metformin-
induced AMPK activation was profoundly reduced in Lkb1
knockout liver and that, strikingly, metformin treatment
failed to produce a glucose-lowering effect in liver-specific
Lkb1 knockout mice rendered hyperglycaemic (by feeding
these mice a fat-enriched diet). Shaw et al proposed that the
LKB1–AMPK signalling controls the expression of key
gluconeogenic genes via the regulation of a transcription
coactivator [45], namely, cAMP response element-binding
protein-regulated transcription coactivator 2 (CRTC2) [46].
In the fasting state, CRTC2 is in a dephosphorylated state and
is localised in the nucleus where it enhances the transcrip-
tional activation of the gluconeogenic genes, including those
encoding peroxisome proliferator-activated receptor-γ
coactivator-1α (Ppargc1a) and its subsequent gluconeogenic
targets such as phosphoenolpyruvate carboxykinase (Pck1)
and glucose-6 phosphatase (G6pc). Feeding (insulin) is
thought to switch off glucose production (at least
partially) through inhibition of gluconeogenic gene
programmes via Akt kinase-signalling-dependent phos-
phorylation and cytoplasmic sequestration of CRTC2
and forkhead box O1 (FOXO1) proteins [47].
Interestingly, metformin can also switch off gluconeo-
genesis independently of insulin/Akt signalling via
LKB1–AMPK pathway. Consistent with this model, in
fasted liver-specific Lkb1 knockout mice, CRTC2 was
localised predominantly in the nucleus, which was
associated with increases in Ppargc1a and G6pc gene
expression, as well as blood glucose levels compared
with control mice [45].
To establish whether the effects of metformin on gluco-
eneogenesis in the liver are mainly mediated through AMPK
or LKB1-dependent kinases (other than AMPK), Foretz et al
[48] recently generated and examined two mouse models in
which genes encoding the AMPKα1 and α2 catalytic
subunits (Prkaa1/2) or LKB1 are knocked out specifically
in hepatocytes. Interestingly, they showed that the adminis-
tration of a bolus injection of metformin to hepatocyte-
specific Prkaa1/2 knockout mice resulted in a glucose-
lowering effect comparable with that observed in control
mice. In addition, treatment of primary hepatocytes lacking
AMPK with metformin displayed a robust inhibition of
glucose production (induced via the membrane-permeable
cAMP analogue dibutyryl cAMP, which mimics the action of
glucagon) and, in fact, the magnitude of inhibition was even
greater than that observed in control wild-type hepatocytes
[48]. Consistent with the observation that liver-specific
Lkb1 knockout mice display higher blood glucose levels in
the fasting state [45], Foretz et al reported that Lkb1−/−
hepatocytes have higher rates of basal/unstimulated and
cAMP-stimulated glucose production compared with
Lkb1+/+ cells. However, unexpectedly, Foretz et al dem-
onstrated that metformin inhibits glucose production
normally in Lkb1 knockout hepatocytes [48]. One potential
explanation for this discrepancy is that Shaw et al did not
assess the immediate effect of metformin administration on
hepatic glucose output by their liver-specific Lkb1
knockout mice, either in vivo or in vitro (primary
hepatocytes) [45]. Instead, they reported that the protective
effect of metformin against hyperglycaemia in response to the
fat-enriched diet was eliminated by repeated administration
(daily injection) of metformin in liver-specific Lkb1 knockout
mice. Thus, it can be speculated that, in the study of Shaw et al,
metformin did not act directly to suppress glucose production
but, rather, might have acted indirectly to protect the
hepatocytes from high-fat diet-induced lipotoxicity and
associated insulin resistance through suppression of lipid
synthesis/lipogenic gene expression (Fig. 1). Finally, it should
be noted that, although the mouse genetic model is a useful
tool, inactivation of critical metabolic gene(s) could possibly
result in compensatory adaptations in alternative pathway(s) to
maintain glucose homeostasis and, in addition, results from
mouse studies are not always applicable to human physiology
and pathology. To date, there is no literature reporting that
patients who have a poor glycaemic response to metformin
have impaired AMPK signalling. There are many loss-of-
function mutations of LKB1 associated with Peutz–Jeghers
cancer syndrome [49]; however, to the best of our knowledge,
these patients have not been found to have a higher incidence
of developing metabolic syndromes such as type 2 diabetes or
insulin resistance, and Lkb1 variants have not convincingly
been reported to play a role in the glycaemic response to
metformin in type 2 diabetes.
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The liver is the main site of action of metformin: the role
of organic cation transporters
Metformin is not metabolised and is excreted in the urine
and bile in an unmodified form. The pharmacokinetics of
metformin are largely determined by its active transport by
key organic cation transporters. Members of this trans-
porter family [50] are involved in active transport across
the gut epithelium and hence determine rates of absorption
(plasma membrane monoamine transporter [PMAT] and
organic cation transporter [OCT] 3), they transport
metformin into hepatocytes (OCT1) and from hepatocytes
into the bile (multidrug and toxic compound extrusion
[MATE] 1) and, finally, into the renal tubular epithelial
cells (OCT2) and into the renal tubule (MATE2) [51]. Oct1
(also known as Slc22a1) knockout mice display reduced
efficacy of metformin [52] and this work has established
an important role for OCT1 in metformin intake and
reinforces the critical role of the liver as the primary site of
action for metformin.
Although metformin exerts its major effect through
inhibition of hepatic glucose production, enhanced glucose
disposal has also been described. Some early studies
suggested that metformin exerts its insulin-sensitising effect
[53] and/or promotes glucose transport independently of the
insulin receptor-mediated proximal signalling pathway in
skeletal muscle [39, 54, 55]. Even though metformin may
accumulate in skeletal muscle and other organs/tissues over
longer periods of time to bring about some effects [56], the
concentration of metformin that was required to acutely
stimulate AMPK and glucose transport in isolated rodent
muscle tissue ex vivo [39] or in cultured muscle cells [54]
was at least two orders of magnitude greater (typically used at
∼1–2 mmol/l and treated for 3–16 h) than those seen in
plasma following the administration of therapeutic doses
(mean plasma concentration of 4.5 μmol/l) [57, 58], making
it unlikely that metformin has amajor therapeutic effect in the
muscle. The potent and preferential effects of metformin in
the liver can be explained by the fact that the drug is supplied
directly from the gut (via the portal vein), which means that a
profoundly higher concentration of metformin (when taken
orally) reaches the liver than other peripheral organs/tissues
[59], and by the high level of expression of OCT1, which
actively transports metformin to its site of action, in
hepatocytes. Metformin has also been reported to have a
protective effect on the vascular endothelium, possibly
explaining the potential cardiovascular benefit of this drug.
This might reflect an indirect benefit owing to a reduction in
hepatic glucose output and circulating insulin, but might also
reflect a direct action of metformin on vascular endothelial
cells, possibly activating AMPK and thereby increasing
nitric oxide synthesis [60, 61] and decreasing reactive
oxygen species through inhibition of complex 1 [62].
Familiar and novel AMPK-independent mechanisms
The mouse genetic study demonstrating that AMPK is not
required for the anti-hyperglycaemic action of metformin
[48] has led to proposals of AMPK-independent mecha-
nisms that may account for the therapeutic effect of
metformin. In the study of Foretz et al [48], two
pharmacological AMPK activators were used: (1) A-
769662, which allosterically stimulates AMPK indepen-
dently of canonical AMP-binding sites located in the
cystathionine β-synthase (CBS) domain of the regulatory
γ-subunit [63, 64], and (2) 5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside (AICAR), an AMP
mimetic. The authors demonstrated that the former failed
to elicit a significant inhibitory effect on glucose output,
but the latter profoundly suppressed glucose output in
hepatocytes isolated from Prkaa1/2 (AMPK) knockout
animals [48], indicating AMP per se but not the AMPK
enzyme may play a vital role in modulating (inhibiting)
hepatic glucose output [50]. They also demonstrated that
metformin elicited a decrease in ATP and a concomitant
rise in AMP levels, and found that there was a tight
correlation between the magnitude of ATP reduction and
inhibition of glucose output. Gluconeogenesis is an
energy-consuming process (requires six molecules of
ATP per molecule of glucose generated); thus, hepatocytes
would be forced to balance energy demand with generation
under conditions of energy stress [65]. Previous work
showed the exquisite control that energy charge can exert
over gluconeogenic flux through allosteric regulation of
key metabolic enzymes in this pathway. For example,
AMP suppresses the gluconeogenic enzyme fructose-1,6-
bisphosphatase [66]. Taken together, these results indicate
that the mitochondrial effects of the drug, which are
upstream of effects of AMPK and therefore independent of
the kinase, might contribute directly to the flux control of
gluconeogenesis [31].
Interestingly, a more recent study has found evidence for
AMPK-independent effects of mitochondrial inhibition on a
canonical signal transduction system that controls hepatic
gluconeogenesis. Miller et al [67] found that metformin and
its sister drug phenformin antagonise effects of the counter-
regulatory hormone glucagon on adenylate cyclase, attenu-
ating glucagon-dependent increases in cAMP levels and
concomitant activation of the cAMP-dependent protein
kinase (known as protein kinase A [PKA]) signalling
pathway. As discussed above, this is the critical signalling
node controlling the gluconeogenic programme during
fasting [47]. These interesting findings build upon earlier
reports that metformin regulates glucagon-dependent cAMP
signalling [68–70]. Phenformin blocked glucagon-induced
cAMP accumulation in AMPK-deficient hepatocytes, dem-
onstrating that this effect is AMPK-independent. Phenformin
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inhibited glucagon-stimulated PKA target phosphorylation
but did not block responses to a membrane-permeable non-
hydrolysable analogue of cAMP, thus verifying that the
reductions in cellular levels of endogenous cAMP are
important for the actions of phenformin. The net concentra-
tion of cAMP can be modulated by synthesis or degradation
(or a combination of the two), which are regulated by
adenylate cyclase and phosphodiesterase, respectively.
Specificity and compartmentalisation of this cAMP signalling
pathway is commonly mediated by the multiplicity of G-
protein-coupled receptors, G-proteins and phosphodiesterases
[71], but these were each excluded in turn from playing a role in
the effects of biguanides [67]. Phosphodiesterases were
excluded on the basis that pharmacological inhibition of these
enzymes did not prevent the ability of phenformin to reduce
cAMP levels [67]. An action of biguanides at the level of G-
proteins or G-protein-coupled receptors was ruled out on the
basis that phenformin reversed cAMP elevation in response to
forskolin [67], which activates adenylate cyclase directly.Miller
et al instead suggest that the incubation of cells with phenformin
leads to inhibitionof adenylate cyclase. This actionof phenformin
is indirect, as it depends on mitochondrial inhibition elevating
cellular AMP concentrations. If this is the case, then how does
AMP switch off cAMP elevation in cells? Miller et al propose
that AMP directly binds to an inhibitory site on adenylate cyclase
called the ‘P-site’. It is worth noting that although there are
several P-site ligands (including adenine, deoxy-adenosine
phosphate and AMP), the physiological/pharmacological
relevance of this regulatory event had been elusive.
Further work will be required to establish to what extent
these effects of phenformin may be extrapolated to
metformin. It may be significant, for example, that the
targeting of glucagon signalling does not readily account for
the lack of hypoglycaemia experienced in response to
metformin use. In this respect, metformin differs from
glucagon receptor knockouts and antagonists, where
hypoglycaemic episodes have been observed [72–74]. An
additional important focus of further work will be to
investigate how targeting of adenylate cyclase enables
biguanides to specifically antagonise glucagon without
affecting signalling through other cAMP signalling path-
ways. To take just one important example, in clinical use,
metformin is not thought to directly affect cardiovascular
variables such as blood pressure [75]. The pharmacokinetics
of metformin, which is predominantly targeted to the liver,
might help to account for this to some extent. On the other
hand, if some of the effects on cAMP signalling are found to
be restricted to phenformin, these could account for the
cardiovascular side effects that were a hallmark of the clinical
experience of phenformin and which ultimately contributed
to its withdrawal [76, 77]. Finally, earlier work has noted
responses to modest concentrations of metformin even in the
presence of hydrolysis-resistant forms of cAMP [48]. Thus,
the relative contributions of cAMP-dependent and cAMP-
independent hepatic effects of metformin will need to be
gauged carefully by further studies.
Conclusion and clinical perspective
After over 50 years of using metformin for the treatment of
type 2 diabetes we continue to learn about how this safe and
effective treatment works. Whilst this in itself is of
considerable biological value, it also starts to pave the way
towards a more targeted approach to therapy and novel drug
development. The most widely accepted model of the anti-
hyperglycaemic action of metformin is that suppression of
hepatic gluconeogenesis occurs principally as a consequence
of mitochondrial inhibition. AMPK, which is activated in
response to mitochondrial inhibitors, including metformin,
has been proposed to be an important effector of metformin.
However, the most recent mouse genetic studies indicate that
suppression of gluconeogenesis may depend more directly
on the mitochondrial respiration rate [48, 78], as was
originally proposed [31], and/or on AMPK-independent
cellular responses to reductions in ATP availability, such as
the recently described effects on cAMP-PKA signalling [67].
In addition, it should be noted that AMPK might play a key
role in long-term effects of metformin by improving lipid
metabolism and mitochondrial function in the liver. From the
recent insights into themechanisms ofmetformin highlighted
in this review, it can be seen that we are finally moving
towards understanding the molecular mechanism of metfor-
min. But what are the clinical implications of these novel
insights? First, we can start to see how understanding the
molecular mechanism can lead to amore targeted approach to
therapy using existing drugs. Second, these novel mecha-
nisms may point towards druggable targets, allowing the
development of novel diabetes therapies.
The glycaemic response to metformin is highly variable,
even after controlling for differences in adherence to
medication. Given the key role of the organic cation
transporters in metformin distribution, these are an area of
ongoing exploration, with a number of loss-of-function
genetic variants described in OCT1 and OCT2. For example,
Shu et al identified several polymorphisms of OCT1 that
displayed a reduced uptake of metformin when ectopically
overexpressed in cultured cells [52]. In this study, a few
variants such as OCT1-Arg61Cys exhibited a reduced
plasma membrane and enhanced cytosolic localisation
compared with the reference OCT1. In some [52, 79, 80],
but not all [81], studies, non-diabetic or diabetic patients
carrying these loss-of-function variants in OCT1 did not
respond to metformin. More work is required to establish
whether these affect more than the glycaemic response (e.g.
vascular, cardiovascular and cancer benefits), and definitive
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genotype stratified clinical trials are required, but it may not
be too long before patients who are not likely to respond to
metformin on the basis of their genotype are offered an
alternative first-line therapy. What about other aspects of
pharmacogenetics? Non-candidate gene approaches recently
revealed a robustly replicated locus associated with the
response to metformin on chromosome 11 [51, 82, 83], with
subsequent follow-up work pointing to the Npat and Atm
genes as the likely causal genes (E. R. Pearson,
R. McCrimmon, M. McCarthy, unpublished data). Future
candidate gene studies focusing on genes involved in copper
transport and exchange, oxidative phosphorylation and the
glucagon/cAMP signalling pathway will establish their
contribution to the therapeutic benefit of metformin.
Ongoing work in this area should provide more insight into
the molecular mechanism of metformin and greater potential
for targeted therapy.
What about new drugs? At first sight, the impressive
safety profile and low cost of metformin itself might
discourage pharmaceutical companies from developing
drugs that act in a similar manner. It should be noted,
however, that the drug is sometimes associated with
uncomfortable gastrointestinal side effects, contributing to
the non-compliance observed in perhaps as many as one-
third of patients initially prescribed it [84]. In addition, type 2
diabetes is a progressive disorder that necessitates additional
medication following failure of metformin monotherapy [1].
Progress in establishing the identity of the clinically
important target(s) and key effectors of metformin will
ultimately enable rational target-based design of more potent
or better-tolerated drugs to support metformin use. For
example, if post-glucagon receptor modification of glucagon
signalling, as reported by Miller et al for phenformin
treatment in rodents [67], can be shown to be an important
effector of metformin therapy in humans, the allosteric
inhibitor P-site on adenylate cyclase provides an alternative
approach to blocking the receptor itself, and this offers an
intriguing novel mechanism for inhibiting glucagon action in
the liver. There are glucagon receptor antagonists in
development and these offer promise as potential therapeutic
agents [73]. However, there is some concern that direct
blockade of the receptor may result in islet hyperplasia, as
seen in rodents in which the glucagon receptor has been
knocked out [72]. Additionally, increases in serum choles-
terol and transaminases have been reported for glucagon
receptor antagonists in clinical trial; effects not seen with
metformin [85]. Whether this reflects its post-glucagon
receptor action or other mechanisms of metformin is unclear.
An alternative approach based on work on the metal-binding
properties of metformin would be to develop agents capable of
directly targeting copper ion transport or exchange. Type 2
diabetes is known to be accompanied by altered copper
handling [86, 87], and work with other drugs has already
demonstrated that drug-based copper sequestration ameliorates
diabetes-related cardiovascular disease, independently of
effects on glycaemia [88, 89]. Consequently, it will be
interesting to study the role of copper binding in the
cardioprotective effects of metformin itself.
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